ACTH therapy benefits stuttering and autism
Adrenocorticotropic hormone therapy in patients with nighttime subclinical seizure activity improves their stuttering and autism symptoms
ACTH therapy improves core symptoms of autism alongside EEG parameters and sublinical seizures.
In a retrospective study a total of 25 patients with attention deficit and hyperactivity (ADHD) or autism spectrum and comorbid stuttering were followed and treated with adrenocorticotropic hormone (ACTH) for electrical status epilepticus in sleep (ESES). Following treatment with ACTH, normalisation of EEG parameters and subclinical epileptiform activity in all the patients was accompanied by a 72% improvement in ADHD or autism symptoms, and 83.8% improvement in stuttering. Twelve of the 25 patients with stuttering showed complete treatment response. The authors noted that the improvement in stuttering had a positive correlation with improvement in ADHD or autism symptoms.
“Stuttering shows a high rate of comorbidity with other developmental disorders such as ADHD and ASD. Language related symptoms in patients with benign focal epilepsies of childhood and LKS also involve stuttering…
The literature reports ESES activity in various developmental disorders. Abnormal epileptiform activities in ADHD/ASD patients have been documented, with an overall prevalence of epileptiform discharges ranging from 14% to 83% in various studies.
Our previous study illustrates that the onset or recurrence of ADHD symptoms is associated with the progressing epileptiform activity; when SWI is around 10–15%, neuropsychiatric symptoms appear. The underlying etiology may play a significant role in the pathophysiology of ESES, stuttering and other comorbidities, thereby connecting ESES to other developmental disorders.
According to the literature enhanced epileptiform activity is associated with cognitive and behavioral impairment while treatment with hormonal therapy is reported to improve language, cognition and behavior.”
References:
Altunel A, Sever A, & Altunel EÖ. (2017) ACTH has beneficial effects on stuttering in ADHD and ASD patients with ESES: A retrospective study. Brain Dev. Feb;39(2):130-137. doi: 10.1016/j.braindev.2016.09.001..
Autism and metabolic diseases – more treatable ‘autisms’ hiding in plain sight?
Metabolism is the process through which our bodies convert nutrients from food and drink into energy. We need energy for the basics of life, such as breathing or blood circulation, and so countless metabolic processes take place in our cells and our organs all the...
Aggression In Autism – One Simple Cause
In addition to the core symptoms of autism, which include social communication difficulties, restricted interests, and sensory processing difficulties, both children and adults with autism often present with many other ‘autism-related’ symptoms and behaviours....
Depression in Autism – More Than Meets The Eye?
High rates of depression and suicide in autism Depression is a common and serious problem in autism, and one of the main contributors to poor quality of life. Both children and adults with autism experience high rates of depression and other mood disorders. One...
Autoimmune Encephalitis – A Treatable Form Of ‘Autism’
Autoimmune encephalitis is a class of inflammatory diseases of the brain that can present with a wide spectrum of neurological and psychiatric symptoms. The word autoimmune means that the body, or the person’s immune system, is attacking its own healthy tissues.What...
‘From Bench to Biopharma’ International Conference on Translational Research in Autism – Day 1 Recap
Synchrony symposia, organised by The BRAIN Foundation in partnership with UC Davis MIND Institute and CalTech, is the first and only international conference on translational research in autism that brings together academia, biotech, pharmaceutical companies and...
NEW UK Autism Research Hub: The Synapse Centre for Neurodevelopment ESNEFT
The Synapse Centre for NeurodevelopmentThe Synapse Centre, based within the ESNEFT (East Suffolk and North Essex NHS Foundation Trust) is a new research centre based in the East of England looking to translate biomedical research into practical therapies for local...
Addressing Poor Health & High Death Rates in Autism
“We must first recognise ASD as a whole body disorder” Autism, or Autism Spectrum Disorder ASD, is traditionally seen as the result of behavioural and neuropsychiatric dysfunction. However there is a strong evidence that various physical, or biomedical, problems can...
Synchrony 2019 – Translational Research in Autism symposia
The first Brain Foundation annual symposia, Pleasanton, California 8-10 of Nov 2019, aimed to connect researchers with clinicians, donors & stake holders to help translate research efforts into evidence-based treatments for autism and its co-morbidities. It highlighted the need for multidisciplinary collaboration, detailed diagnostics and personalised treatment…
Transcranial direct current stimulation tDCS – a novel treatment for autism?
One of the treatment modalities that has shown the greatest promise for reducing symptoms of autism in recent years is transcranial direct current stimulation (tDCS). The most recent study confirmed and expanded on the findings of previous investigations, which strongly indicate that tDCS could have positive effects on cognition, behaviour and physical health, and improve quality of life and autonomy for a large percentage of individuals with autism.
Cannabis for Treating Core and Comorbid Autism Symptoms – Where are we at?
Several studies published in recent months investigated the effects of cannabis-based products for treating autism. Although the studies were open-label and relatively small in scale, the overall results were overwhelmingly positive, with statistically significant improvements in social communication, language, restrictive/repetitive and challenging behaviours.
Century-old drug offers new hope for autism treatment
A small double-blind, placebo-controlled trial shows dramatic effects of suramin as a treatment for autism. Improvements were seen in all three core features of autism: language, social interactions, and restricted or repetitive behaviours across multiple diagnostics in multiple tests in all who received the active treatments, absent in the placebo arm
Higher rates of autism in children with various congenital disorders
Children with Congenital Heart Disease, Tuberous Sclerosis Complex, Duchenne Muscular Dystrophy, Ehlers-Danlos Syndrome, Neurofibromatosis Type 1 suffer high rates of autism. Everolimus, an mTOR inhibitor with strong neuro-inflammation attenuating effects, reduces core autism symptoms in some children with TSC, epilepsy and autism…